In order to explore the critical efficiency of S100A2/4/6/10/14/16 in the survival of patients with pancreatic cancer, GEPIA2, UALCAN and Kaplan-Meier Plotter tools, whose data sources include GEO, EGA, and TCGA, were used to analyze the prognostic values (OS) of the mRNA expression of S100As in pancreatic cancer patients. This evidence concerns the gene S100A2 and familial pancreatic carcinoma.